Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;17(6):493-8.
doi: 10.5114/wo.2013.38911. Epub 2013 Dec 19.

Prognostic value of NF-κB, CD9, and VEGF in gastrointestinal stromal tumors

Arzu Tasdemir  1 , Isin Soyuer  2 , Dilek Unal  3 , Tarik Artis  4
Affiliations

Prognostic value of NF-κB, CD9, and VEGF in gastrointestinal stromal tumors

Arzu Tasdemir et al. Contemp Oncol (Pozn). 2013.

Abstract

Aim of the study: Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors of the gastrointestinal system. We aimed to determine whether nuclear transcription factor κB (NF-κB), CD9 and vascular endothelial growth factor (VEGF) have prognostic value in patients with GIST.

Material and methods: Thirty-five patients with GIST, who were diagnosed in the Pathology Department of Erciyes University, were included in the study. Cases were classified based on the 2002 NIH consensus. CD9, VEGF, and NF-κB immunohistochemistry were applied to GIST cases positive for CD117 and CD34, which are used to evaluate GISTs immunohistochemically.

Results: Although there are no statistically significant differences between NF-κB (p = 0.329), CD9 (p = 0.269), and VEGF (p = 0.372) and risk groups, 79.22% of cases that stained positive for NF-κB, 81% of cases that stained positive for CD9, and 80% of cases that stained positive of VEGF were in the high risk group.

Conclusions: It was found that NF-κB, CD9, and VEGF, which are important in predicting behaviors of other malign tumors, were expressed at high rates in high risk group GISTs. This can be used to determine prognosis with tumor diameter, mitosis rate under 50 BBS, Ki-67 proliferation index and other parameters.

Keywords: CD9; NF-κB; VEGF; gastrointestinal stromal tumor.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A) Spindle cell, low-risk GIST (hematoxylin and eosin staining, magnification 10×), B) High-risk GIST (hematoxylin and eosin staining, magnification 40×)
Fig. 2
Fig. 2
Gross appearance of liver metastasis from GIST
Fig. 3
Fig. 3
Positive immunohistochemical staining with NF-κB (A), CD9 (B), and VEGF (C) (magnification 20×)
See this image and copyright information in PMC

References

    1. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1–12. - PubMed
    1. Miettinen M, Sobin LH, Sarloma-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117(KIT) Mod Pathol. 2000;13:1134–42. - PubMed
    1. Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol Int. 2006;56:1–9. - PubMed
    1. Park S, Kim M, Kim H, Song BJ, Chi JG. Ultrastructural Studies of Gastrointestinal Stromal tumors. J Korean Med Sci. 2004;19:234–44. - PMC - PubMed
    1. Nilsson B, Bümming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG. Gastrointestinal Stromal Tumors: The Incidence, Prevalence, Clinical Course, and Prognostication in the Preimitanib Mesylate Era. Cancer. 2005;103:821–9. - PubMed

LinkOut - more resources